EX-10.5





 Exhibit 10.5 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN
ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 
 CONVERTIBLE PROMISSORY NOTE

  

			
	
$[                    ]
	  	[    ], 2017

 For value received, Grace Therapeutics LLC, a New Jersey limited liability company (the
“Company”), promises to pay to [                ] (the “Holder”), the principal sum of
[                                    ] Dollars
($[                ]). Interest shall accrue from the date of this Note on the unpaid principal amount at a rate equal to six percent (6%) per annum, compounded
annually. This Note is one of a series of Convertible Promissory Notes containing substantially identical terms and conditions issued pursuant to that certain Convertible Promissory Note Purchase Agreement dated
[    ], 2017 (the “Purchase Agreement”). Such Notes are referred to herein as the “Notes,” and the holders thereof are referred to herein as the “Holders.” This
Note is subject to the following terms and conditions. 
 1.    Maturity. Unless
converted as provided in Section 2, this Note will automatically mature and be due and payable on December 31, 2018 (the “Maturity Date”). Subject to Section 2 below, interest shall accrue on this Note but shall not
be due and payable until the Maturity Date. Notwithstanding the foregoing, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, shall become immediately due and payable upon the insolvency of the Company,
the commission of any act of bankruptcy by the Company, the execution by the Company of a general assignment for the benefit of creditors, the filing by or against the Company of a petition in bankruptcy or any petition for relief under the federal
bankruptcy act or the continuation of such petition without dismissal for a period of ninety (90) days or more, or the appointment of a receiver or trustee to take possession of the property or assets of the Company. 

2.    Conversion. 

(a)    Investment by the Holder. The entire principal amount of and accrued interest
on this Note shall be converted into shares, units or percentage interests (as applicable, “Units”) of the Company’s equity securities (the “Equity Securities”) issued and sold at the close of the
Company’s next equity financing in a single transaction or a series of related transactions yielding gross proceeds to the Company of at least five million dollars ($5,00,000) in the aggregate (excluding the conversion of the Notes) (the
“Next Equity Financing”). The number of Units to be issued upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) eighty percent
(80%) of the price per Unit being offered in such Next Equity Financing, rounded to the nearest whole Unit, and the issuance of such Units upon such conversion shall be upon the terms and subject to the conditions applicable to the Next Equity
Financing. 
 (b)    Mechanics and Effect of Conversion. No fractional Units will
be issued upon conversion of this Note. In lieu of any fractional Unit to which the Holder would otherwise be entitled, the Company will pay to the Holder in cash the amount of the unconverted principal and interest balance of this Note that would
otherwise be converted into such fractional Unit. Upon conversion of this Note pursuant to this Section 2, the Holder shall surrender this Note, duly endorsed, at the principal offices of the Company or any transfer agent of the Company. At its
expense, the Company will, as soon as practicable thereafter, issue and deliver to such Holder, at such principal office, a certificate or certificates for the number of Units to which such Holder is entitled upon such conversion, together with any
other securities and property to which the Holder is entitled upon such conversion 












 
under the terms of this Note, including a check payable to the Holder for any cash amounts payable as described herein. Upon conversion of this Note, the Company will be forever released from all
of its obligations and liabilities under this Note with regard to that portion of the principal amount and accrued interest being converted including without limitation the obligation to pay such portion of the principal amount and accrued interest.

 3.    Payment; Prepayment. All payments shall be made in lawful money of the
United States of America at such place as the Holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable and the remainder applied to principal. Prepayment of
this Note may be made at any time without penalty, provided that all of the Notes shall be prepaid on a pro rata basis. 

4.    Transfer; Successors and Assigns. The terms and conditions of this Note shall
inure to the benefit of and be binding upon the respective successors and assigns of the parties. Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer this Note without the prior written consent of the Company,
except for transfers to affiliates that agree in writing to be bound by the terms of this Note and the Purchase Agreement. Subject to the preceding sentence, this Note may be transferred only upon surrender of the original Note for registration of
transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to, and registered in the name of, the
transferee. Interest and principal are payable only to the registered holder of this Note. 

5.    Governing Law. This Note and all acts and transactions pursuant hereto and the
rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of New Jersey, without giving effect to principles of conflicts of law. 

6.    Notices. Any notice required or permitted by this Agreement shall be in writing
and shall be deemed sufficient upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or forty eight (48) hours after being deposited in the U.S. mail as certified or registered mail with
postage prepaid, if such notice is addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice. 

7.    Amendments and Waivers. Any term of this Note may be amended only with the
written consent of the Company and Holders holding at least sixty six percent (66%) of the then-outstanding principal and interest of the Notes. Any amendment or waiver effected in accordance with this Section 7 shall be binding upon the
Company, each Holder and each transferee of any Note. 
 8.     Members, Officers and Managers Not
Liable. In no event shall any member, officer or manager of the Company be liable for any amounts due or payable pursuant to this Note. 

9.    Counterparts. This Note may be executed in any number of counterparts, each of
which will be deemed to be an original and all of which together will constitute a single agreement. 

10.    Loss of Note. Upon receipt by the Company of evidence satisfactory to it of
the loss, theft, destruction or mutilation of this Note or any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation of such Note (in the case of mutilation), the
Company will make and deliver in lieu of such Note a new Note of like tenor. 
 [Signature Page Follows] 

  
 -2- 













 The parties have executed this Convertible Promissory Note as of the date
first written above. 
  

			
	 COMPANY:

	
	 GRACE THERAPEUTICS LLC

		
	 By:
	 	  

	 Name:

	 Title:

	
	 Address:



  

			
	 AGREED TO AND ACCEPTED:

	
	 [HOLDER]

		
	 By:
	 	  

	
	 Name:
[                                        
]

	
	 Title:
[                                        
]

		
	 Address:
	 	
[                ]